Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations
暂无分享,去创建一个
Matthew Franklin | James Lomas | Gerry Richardson | M. Franklin | G. Richardson | James Lomas | J. Lomas
[1] Karl Claxton,et al. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. , 2009, Health policy.
[2] Tracey A. Young,et al. Estimating mean total costs in the presence of censoring , 2012, PharmacoEconomics.
[3] A. Detsky,et al. Relevance of cost-effectiveness analysis to clinicians and policy makers. , 2007, Journal of the American Medical Association (JAMA).
[4] D. Altman,et al. Distinguishing Case Series From Cohort Studies , 2012, Annals of Internal Medicine.
[5] J. Lellouch,et al. Explanatory and pragmatic attitudes in therapeutical trials. , 1967, Journal of chronic diseases.
[6] Yaling Yang,et al. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement , 2018, Health and Quality of Life Outcomes.
[7] M. Franklin,et al. The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation. , 2018, Health technology assessment.
[8] Michael Drummond,et al. Economic evaluation for devices and drugs--same or different? , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] Zoltán Kaló,et al. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] M. Drummond,et al. Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.
[11] Maarten J. IJzerman,et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] B. Prendergast,et al. The Cost-Effectiveness of Antibiotic Prophylaxis for Patients at Risk of Infective Endocarditis , 2016, Circulation.
[13] S. Griffin,et al. Distributional cost-effectiveness analysis: a tutorial , 2016 .
[14] C. McKevitt,et al. The potential role of cost-utility analysis in the decision to implement major system change in acute stroke services in metropolitan areas in England , 2018, Health Research Policy and Systems.
[15] William H Crown,et al. Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods , 2014, Applied Health Economics and Health Policy.
[16] A. Schuh,et al. Issues surrounding the health economic evaluation of genomic technologies. , 2013, Pharmacogenomics.
[17] R. Edwards,et al. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues , 2013, BMC Public Health.
[18] S. van den Broucke. Implementing health in all policies post Helsinki 2013: why, what, who and how. , 2013, Health promotion international.
[19] J. Raftery,et al. NICE’s Cost-Effectiveness Range: Should it be Lowered? , 2014, PharmacoEconomics.
[20] J. Grimshaw,et al. Systematic review of economic evaluations and cost analyses of guideline implementation strategies , 2007, The European Journal of Health Economics.
[21] E. Faerstein,et al. A DICTIONARY OF EPIDEMIOLOGY , 2016 .
[22] S. Petrou. Rationale and methodology for trial-based economic evaluation , 2012 .
[23] Andrew R Willan,et al. Regression methods for cost‐effectiveness analysis with censored data , 2005, Statistics in medicine.
[24] Karl Claxton,et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.
[25] James Lomas,et al. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data , 2018, BMJ Global Health.
[26] P. van Baal,et al. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future , 2018, PharmacoEconomics.
[27] Huseyin Naci,et al. A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. , 2019, Journal of clinical epidemiology.
[28] Miquel Porta,et al. A Dictionary of Epidemiology , 2008 .
[29] Steve Goodacre,et al. Uncontrolled before-after studies: discouraged by Cochrane and the EMJ , 2015, Emergency Medicine Journal.
[30] S. Palmer,et al. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator? , 2020, PharmacoEconomics.
[31] Philip Jones,et al. Public Finance and Public Choice (2nd ed) , 1998 .
[32] K. Marsh,et al. Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature , 2014, PharmacoEconomics.
[33] B. O'brien,et al. The death of cost-minimization analysis? , 2001, Health economics.
[34] Jon Sussex,et al. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold , 2013 .
[35] S Bryan,et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation. , 2008, Health technology assessment.
[36] A. Fischer,et al. Additional Elements of Value for Health Technology Assessment Decisions , 2017 .
[37] J. Brazier,et al. Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY , 2015, Applied Health Economics and Health Policy.
[38] N. Booth. On value frameworks and opportunity costs in health technology assessment , 2019, International Journal of Technology Assessment in Health Care.
[39] A H Briggs,et al. Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.
[40] Anthony J Culyer,et al. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use , 2016, Health Economics, Policy and Law.
[41] Kelly Hall,et al. Social Return on Investment (SROI) and Performance Measurement , 2013 .
[42] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[43] Gianluca Baio,et al. A Review of Methods for Analysis of the Expected Value of Information , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.
[44] Mohit Bhandari,et al. Principles of evidence-based medicine. , 2010, The Orthopedic clinics of North America.
[45] T C Chalmers,et al. Randomized versus historical controls for clinical trials. , 1982, The American journal of medicine.
[46] J. Greene,et al. Assessing the Gold Standard--Lessons from the History of RCTs. , 2016, The New England journal of medicine.
[47] H. C. Mann,et al. The Impact Test , 1938 .
[48] S. Dopson,et al. The limitations of QALY: a literature review , 2016 .
[49] A. Akobeng. Understanding randomised controlled trials , 2005, Archives of Disease in Childhood.
[50] A. Street,et al. Economic analysis of service and delivery interventions in health care , 2018 .
[51] J. Oakley,et al. Estimating multi-parameter partial Expected Value of Perfect Information from a probabilistic sensitivity analysis sample : a non-parametric regression approach , 2013 .
[52] T. Frieden. Evidence for Health Decision Making — Beyond Randomized, Controlled Trials: The Changing Face of Clinical Trials , 2017, The New England journal of medicine.
[53] John Brazier,et al. Development of the Scharr HUD (Health Utilities Database) , 2013 .
[54] E. Wilson. A Practical Guide to Value of Information Analysis , 2015, PharmacoEconomics.
[55] S. Giordano,et al. Randomized Clinical Trials and Observational Studies: Is There a Battle? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] J. Coast,et al. Use of economic evaluation in local health care decision-making in England: a qualitative investigation. , 2009, Health policy.
[57] Jeremy E. Oakley,et al. Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.
[58] G. Tomlinson,et al. Techniques for estimating health care costs with censored data: an overview for the health services researcher , 2012, ClinicoEconomics and outcomes research : CEOR.
[59] The NIHR at 10: transforming clinical research . , 2016, Clinical medicine.
[60] S. Capewell,et al. Return on investment of public health interventions: a systematic review , 2017, Journal of Epidemiology & Community Health.
[61] M. Kelly,et al. Designing and Undertaking a Health Economics Study of Digital Health Interventions. , 2016, American journal of preventive medicine.
[62] Maarten J. IJzerman,et al. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[63] M. Soares,et al. Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[64] E. McIntosh,et al. Applied Health Economics for Public Health Practice and Research , 2019 .
[65] A. Gasparrini,et al. Interrupted time series regression for the evaluation of public health interventions: a tutorial , 2016, International journal of epidemiology.
[66] M. Franklin,et al. A modelling-based economic evaluation of primary-care-based fall-risk screening followed by fall-prevention intervention: a cohort-based Markov model stratified by older age groups , 2019, Age and ageing.
[67] D. Rowen,et al. International Regulations and Recommendations for Utility Data for Health Technology Assessment , 2017, PharmacoEconomics.
[68] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.
[69] D. Spiegelhalter,et al. Cancer Drugs Fund requires further reform , 2016, British Medical Journal.
[70] C. Carroll,et al. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis. , 2011, Health technology assessment.
[71] G. Richardson,et al. Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments , 2018, International journal of environmental research and public health.
[72] Joshua T. Cohen,et al. When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs , 2017, PLoS medicine.
[73] Rob Anderson,et al. Realism and resources: Towards more explanatory economic evaluation , 2016, Evaluation.
[74] D. Rovithis. Do health economic evaluations using observational data provide reliable assessment of treatment effects? , 2013, Health Economics Review.
[75] S. Griffin,et al. Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.
[76] Jessica M Franklin,et al. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.
[77] Bengt Jönsson,et al. Ten arguments for a societal perspective in the economic evaluation of medical innovations , 2009, The European Journal of Health Economics.
[78] Elisabeth Fenwick,et al. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[79] R. Meacock. Methods for the economic evaluation of changes to the organisation and delivery of health services: principal challenges and recommendations , 2018, Health Economics, Policy and Law.
[80] G. Rinkel,et al. Decision analysis to complete diagnostic research by closing the gap between test characteristics and cost-effectiveness. , 2009, Journal of clinical epidemiology.
[81] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[82] Matthew Franklin,et al. Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future , 2019, BMC Medical Research Methodology.
[83] J. Poterba. PUBLIC FINANCE AND PUBLIC CHOICE , 1998, National Tax Journal.
[84] Nicholas R Latimer,et al. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[85] Anthony J. Culyer,et al. The NICE Cost-Effectiveness Threshold , 2012, PharmacoEconomics.
[86] Jeremy Cherfas,et al. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial , 2018, British Medical Journal.
[87] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[88] S. Whyte,et al. Distributional cost-effectiveness analysis of health care programmes--a methodological case study of the UK Bowel Cancer Screening Programme. , 2013, Health economics.
[89] S. Bryan,et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. , 2008, Health technology assessment.
[90] Joanna Coast,et al. A systematic review of the use of economic evaluation in local decision-making. , 2008, Health policy.
[91] P. McFarlane,et al. Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis , 2012, PharmacoEconomics.
[92] J. Brazier,et al. An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values , 2019, Applied Health Economics and Health Policy.
[93] P. Austin,et al. Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies , 2008 .
[94] D. H. Lees,et al. Epidemiology for the Uninitiated , 1980 .
[95] Christopher Jackson,et al. Value of Information: Sensitivity Analysis and Research Design in Bayesian Evidence Synthesis , 2017, Journal of the American Statistical Association.
[96] Identifying patient-level health and social care costs for older adults discharged from acute medical units in England. , 2014, Age and ageing.
[97] K. Schulz,et al. Descriptive studies: what they can and cannot do , 2002, The Lancet.
[98] D. Meltzer,et al. Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al. , 2013, PharmacoEconomics.
[99] R. Cookson,et al. Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia , 2018, Health policy and planning.
[100] J. Grimshaw,et al. The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[101] M. Deidda,et al. A framework for conducting economic evaluations alongside natural experiments , 2019, Social science & medicine.
[102] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[103] Ties Hoomans,et al. Economic evaluation of implementation strategies in health care , 2014, Implementation Science.
[104] J. Concato,et al. Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.
[105] Peter Littlejohns,et al. Cost effective but unaffordable: an emerging challenge for health systems , 2017, British Medical Journal.
[106] J. Nelson,et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. , 2006, International journal of epidemiology.
[107] M. Franklin,et al. Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study , 2017, PharmacoEconomics.
[108] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[109] Andy Stergachis,et al. The Role of Cost—Consequence Analysis in Healthcare Decision—Making , 1998, PharmacoEconomics.
[110] J. Lewis,et al. Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. , 1999, Statistics in medicine.
[111] T J Ulahannan,et al. Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .
[112] P. Kind,et al. The use of QALYs in clinical and patient decision-making: issues and prospects. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[113] S. Sullivan,et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[114] J. Sekhon,et al. Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation , 2013, Health Services and Outcomes Research Methodology.
[115] S. Hinde,et al. Understanding and addressing the challenges of conducting quantitative evaluation at a local level: a worked example of the available approaches , 2019, BMJ Open.
[116] G. Loomes,et al. The use of QALYs in health care decision making. , 1989, Social science & medicine.
[117] Matthew Franklin,et al. An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis , 2019, PharmacoEconomics.
[118] James Lomas,et al. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[119] S. Dixon,et al. Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available? , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[120] S. Walker,et al. Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers , 2019, Applied Health Economics and Health Policy.
[121] Jeremy E. Oakley,et al. Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[122] N. Freemantle,et al. An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis , 2015, PharmacoEconomics.
[123] Timo Siepmann,et al. Randomized controlled trials – a matter of design , 2016, Neuropsychiatric disease and treatment.
[124] R. Faria,et al. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence , 2016, PharmacoEconomics.
[125] A. Culyer. COST, CONTEXT, AND DECISIONS IN HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT , 2018, International Journal of Technology Assessment in Health Care.
[126] D. Hunter. Efficiency and the proposed reforms to the NHS research ethics system , 2007, Journal of Medical Ethics.
[127] S. Pearson. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.